The Egyptian Drug Authority, led by Dr. Ali Al-Gamrawi, recently held a meeting with representatives from several Korean companies participating in the Global Market Expansion Program (GMEP). The meeting aimed to discuss opportunities for these companies to enter the Egyptian market and explore the regulatory requirements and procedures for circulating their products in Egypt. This move is part of the authority's efforts to support investment and enhance international cooperation in the healthcare sector.
The meeting was attended by high-ranking officials from Korean companies, including Dr. Youngsoon Yu, CEO of Yooth Oclock, Dr. Hyunjung (John) Lim, CEO of Befour, and Dr. Jongmin Byun, CEO of NX Biomed. Also present were Dr. Manyeong Han, CEO of Strategy at K-Style Hub, and Byeongwoo Kang, Sales Manager at Wellbiz International. The Egyptian side was represented by Hania Tariq, Director of the Egypt Office, and Mia Sirwar, Regional Operations Coordinator at Blag & Play.
Dr. Ali Al-Gamrawi emphasized the authority's commitment to supporting cooperation with international companies interested in entering the Egyptian market. He highlighted the authority's role in providing necessary technical and regulatory clarifications on product registration and circulation procedures. This support is aimed at facilitating procedures according to approved frameworks and regulations, thereby enhancing the attractiveness of the Egyptian market for health-related investments.
Representatives from the Korean companies expressed their interest in investing in the Egyptian market and discussed the requirements and procedures for registering their products. They acknowledged the importance of the Egyptian market as a strategic gateway to African and European markets, which could expand their regional presence and open up new investment opportunities.
The meeting covered various topics, including the regulatory pathways for cosmetics, personal care products, and medical devices. Discussions also focused on procedures for importing finished products from Korea to Egypt and the possibility of conducting local packaging and labeling. These deliberations reflect the companies' interest in expanding their presence in the Egyptian market and exploring new cooperation and investment opportunities.
This meeting aligns with the Egyptian Drug Authority's efforts to enhance communication with investors and international companies, clarifying the regulatory frameworks governing product circulation. The authority aims to balance facilitating investment with compliance with regulatory requirements, ensuring product quality and safety to protect public health and promote Egypt's investment environment.
The Egyptian Drug Authority has been actively engaging with various international companies to promote cooperation and investment in the pharmaceutical sector. Recent meetings have been held with companies such as Pfizer, Novartis, and InnoVax, focusing on topics like developing the drug system, localizing biotech industries, and ensuring the availability of thyroid treatment products.
Key points
- The Egyptian Drug Authority is keen on supporting international cooperation and investment in the healthcare sector.
- The authority provides technical and regulatory guidance to facilitate the entry of foreign products into the Egyptian market.
- Egypt is seen as a strategic hub for accessing African and European markets, making it an attractive destination for investors.
